Hoffmann-la Roche Inc.

Rigel Pharmaceuticals, Incorporated

Glaxo Inc.

Mycosol, Inc.

Endacea, Inc.

Smithkline Beecham Corporation

Glaxo Group Limited

Glaxo Wellcome Inc.

Debiopharm International, S.a.

Other

University of Minnesota

Neurotherapeutics Pharma, Inc.

Neuropro Therapeutics, Inc.

John Joseph Partridge

Milan R Uskokovic

Rajinder Paul Singh

Dane A Goff

Shian-Jan Shiuey

Brian L Bray

Richard Barry Klein

Jeffrey Leaman Selph

Constance Neely Wilson

Naresh K Chadha

John Reinhard

Robert Anthony Mook

Henry Lu

Alfred Boris

John W Lackey

Ankush Argade

Sacha Holland

Jeffrey Clough

Catherine Sylvain

Anthony Marfat

Jing Zhang

Robert J Zamboni

Michel Therien

John Colucci

Daryl W Hochman

David Lee Musso

Gary A Truitt

Yves Gareau

Helmi Zaghdane

John P Turnbull

Maynard Emanuel Lichty

Phillip Frederick Morgan

Mark L Peterson

Barry Hafkin

Enrico G Baggiolini

David L Coffen

Percy Sarwood Manchand

Tai-Nang Huang

Steve Yik-Kai Tam

Panayiotis Kalaritis

Peter S Belica

In part, the present disclosure is directed to prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide compounds with significant solubility and bioavailability profiles.

Prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide

The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the NaKClco-transporter or GABAreceptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma. Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

Bumetanide analogs, compositions and methods of use

Prodrug derivatives of (E)-N-methyl-N-((3-M ethylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide

Methods of using triazole derivatives in treating diseases or conditions associated with Axl catalytic activity are disclosed.

Triazole derivatives useful as Axl inhibitors

Pegylated pyridinium and thiazolium compounds and methods of their use in medicine, research, industry, agriculture and recreational activities are disclosed. The present invention also provides methods of controlling microbial growth and infection. Additionally, the present invention provides methods of controlling microbial infestations relating to industrial and agricultural uses. The present invention can also be used to control insects.

Pyridinium and thiazolium conjugates including polyethylene glycols and methods of using the same

Compounds of pyridinium salts and methods of their use in medicine, particularly in the prophylaxis and treatment of inflammatory conditions, infectious conditions, as well as immune disorders are disclosed. The present invention also relates to methods of controlling fungi and/or bacteria.

Methods of treating inflammations and infections with pyridinium salts

The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na&#x2014;K-2Cl(NKCC) cotransporter. In certain embodiments, the Na&#x2014;K-2Clco-transporter is NKCC1.

Methods and compositions for the treatment of neuropsychiatric disorders

 The present invention provides novel adenosine receptor antagonists, more particularly, Aadenosine receptor antagonists of formula (I). Pharmaceutical compositions comprising an Aadenosine receptor antagonist of formula (I) and a pharmaceutically acceptable carrier are further provided. Compositions also include diagnostic assay-type probes comprising a novel Aadenosine receptor antagonist of formula (I) that is labeled or conjugated with radioactive or non-radioactive material. Methods for treating Aadenosine receptor related disorders comprising administering an Aadenosine receptor antagonist of formula I are also disclosed. The novel Aadenosine receptor antagonist compositions of formula (I) find further use in diagnostic and imaging methods.

[object Object]

Triazole derivatives and pharmaceutical compositions containing the derivatives are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the derivatives in treating diseases or conditions associated with Axl catalytic activity are also disclosed.

The present invention includes compounds of pyridinium salts and methods of their use for industrial uses. The present invention also relates to methods of controlling fungi and/or bacteria. The present invention may also be used to control insects.

Compounds and methods for controlling fungi, bacteria and insects

The present invention relates to pyridyl substituted heterocycles and hydro isomers thereof and pharmaceutical compositions thereof that inhibit replication and/or proliferation of HCV virus. The present invention also relates to the use of the pyridyl heterocycles and hydro isomers thereof and/or pharmaceutical compositions comprising the compounds to treat or prevent HCV infections.

Pyridyl substituted heterocycles useful for treating or preventing HCV infection

The present invention includes compounds of pyridinium salts and methods of their use for agricultural purposes. The present invention also relates to methods of controlling fungi and/or bacteria.

Methods for controlling fungi and bacteria

Compounds of the general formula (I) are described: wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described.

A1 adenosine receptor antagonists

The present invention relates to substituted diphenylisoxazole compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

Diphenylisoxazole compounds and hydro isomers thereof

Growing community of inventors

Chapel Hill, NC, United States of America

John Joseph Partridge